Daiichi Sankyo: all 498 studies

Page 4 of 5. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.

• Study of VN-0200 in Japanese Healthy Adults and Elderly SubjectsCompletedNCT04914520Phase 1
• Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly SubjectsCompletedNCT04821674Phase 1/2
• Study of Single-Ascending Doses of DS-6016a in Healthy Japanese SubjectsCompletedNCT04818398Phase 1
• Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in ChinaCompletedNCT04747496
• A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsActive, not recruitingNCT04707248Phase 1
• Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Phase 3
• HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingNCT04676477Phase 1
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Active, not recruitingNCT04622319Phase 3
• Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in TurkeyCompletedNCT04594915
• Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed DyslipidemiaActive, not recruitingNCT04579367
• Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)Active, not recruitingNCT04526691Phase 1
• Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary InterventionCompletedNCT04519944
• A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II GliomaActive, not recruitingNCT04458272Phase 2
• Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular DystrophyActive, not recruitingNCT04433234Phase 2
• A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT04419532Phase 1
• Study of Single-dose DS-3201b in Participants With Hepatic ImpairmentCompletedNCT04276662Phase 1
• Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic DermatitisTerminatedNCT04211415Phase 1
• Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant TumorsActive, not recruitingNCT04145622Phase 1/2
• Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/LymphomaCompletedNCT04102150Phase 2
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic PainCompletedNCT04094662Phase 3
• DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerActive, not recruitingNCT04042701Phase 1
• Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)CompletedNCT04033094
• The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy VolunteersCompletedNCT04019652Phase 1
• Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodActive, not recruitingNCT03793478Phase 1/2
• Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive QuizartinibNo longer availableNCT03746912
• Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT03723681Phase 1
• Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy VolunteersCompletedNCT03699774Phase 1
• Food Effects on Milademetan Pharmacokinetics in Healthy ParticipantsCompletedNCT03647202Early Phase 1
• Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy ParticipantsCompletedNCT03614455Early Phase 1
• First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)Active, not recruitingNCT03401385Phase 1
• DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)WithdrawnNCT03316729Phase 2
• DS2330b Alone and With Sevelamer in Patients on Chronic HemodialysisCompletedNCT03305471Phase 1
• U3-1402 in Metastatic or Unresectable Non-Small Cell Lung CancerActive, not recruitingNCT03260491Phase 1
• Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)CompletedNCT03247582
• Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)CompletedNCT03247569
• Effect of Probenecid on Pexidartinib PharmacokineticsCompletedNCT03138759Phase 1
• Study of DS-1001b in Patients With Gene IDH1-Mutated GliomasCompletedNCT03030066Phase 1
• Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal CancerTerminatedNCT02991196Phase 1
• Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical OutcomesCompletedNCT02964949Not applicable
• Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)CompletedNCT02952599
• Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)CompletedNCT02951039
• Edoxaban Management in Diagnostic and Therapeutic ProceduresCompletedNCT02950168
• Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial FibrillationCompletedNCT02944019
• Study of CS-3150 in Patients With Essential HypertensionCompletedNCT02890173Phase 3
• Study of CS-3150 in Patients With Primary AldosteronismCompletedNCT02885662Not applicable
• Study of CS-3150 Compared to Olmesartan in Patients With Essential HypertensionCompletedNCT02848170Not applicable
• Study of CS-3150 in Patients With Severe HypertensionCompletedNCT02808026Phase 3
• Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal ImpairmentCompletedNCT02807987Phase 3
• Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and AlbuminuriaCompletedNCT02807974Phase 3
• A Study Assessing the Mass Balance of a Single Oral Dose of [14C] DS-8500a in Healthy SubjectsCompletedNCT02790684Phase 1
• A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy SubjectsCompletedNCT02790671Phase 1
• DS-3201b in Participants With LymphomasActive, not recruitingNCT02732275Phase 1
• Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential HypertensionCompletedNCT02722265Phase 3
• An Open Study Assessing the Safety and Tolerability of U3-1784TerminatedNCT02690350Phase 1
• Study of DS-1123a in Advanced Solid TumoursCompletedNCT02690337Phase 1
• A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving SitagliptinCompletedNCT02685345Phase 2
• A Study of PLX51107 in Advanced MalignanciesTerminatedNCT02683395Phase 1
• Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant TumorsCompletedNCT02675491Phase 1
• Phase 1 Study of QuizartinibCompletedNCT02675478Phase 1
• Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)WithdrawnNCT02673866Phase 2
• A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell TumorTerminatedNCT02673736Phase 1
• An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic ClampCompletedNCT02669732Not applicable
• Study of the Effects of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of DS-1040bCompletedNCT02647307Phase 1
• A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02628392Not applicable
• Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute TraumaCompletedNCT02616068Phase 3
• Multiple Dose Study of D1971a in Healthy VolunteersCompletedNCT02564861Phase 1
• Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy SubjectsCompletedNCT02560688Phase 1
• Study of DS-7080a for the Treatment of Macular DegenerationCompletedNCT02530918Phase 1
• Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic ArteriolopathyWithdrawnNCT02527213Phase 3
• Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney DiseaseCompletedNCT02492672
• A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTSCompletedNCT02473627Phase 1
• A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal ImpairmentCompletedNCT02448628Phase 2
• Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck CancerCompletedNCT02350712Phase 1
• A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With MicroalbuminuriaCompletedNCT02345057Phase 2
• A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive SubjectsCompletedNCT02345044Phase 2
• Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney DiseaseCompletedNCT02299661Phase 1
• Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a TabletsCompletedNCT02266940Phase 1
• Effects of Age, Gender & Race on the Pharmacokinetics (PK)of DS-1971aCompletedNCT02261376Phase 1
• Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute StrokeWithdrawnNCT02258880Phase 2
• Phase 2 Study of DS-8500a in Patients With Type 2 DiabetesCompletedNCT02222350Phase 2
• Open Label Study of DS-5573aTerminatedNCT02192567Phase 1
• Multiple Dose Study of DS-1971aCompletedNCT02190058Phase 1
• Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic ImpairmentCompletedNCT02150733Phase 1
• Multiple Ascending Dose Study of DS-1093 in Healthy SubjectsCompletedNCT02142400Phase 1
• Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.CompletedNCT02107885Phase 1
• Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT02076451Phase 1
• DS1040b/Aspirin Drug/Drug Interaction StudyCompletedNCT02071004Phase 1
• A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on AnticoagulationCompletedNCT02047565Phase 1
• Phase 1 Study of DS-8895a in Subjects With Advanced Solid TumorsCompletedNCT02004717Phase 1
• Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes MellitusCompletedNCT02004678Phase 1
• Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency AnemiaCompletedNCT01984554
• Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)CompletedNCT01957280Phase 1
• Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose StudyCompletedNCT01956305Phase 1
• A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes MellitusCompletedNCT01862939Phase 1
• Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination TherapyCompletedNCT01838850Phase 3
• Pharmacokinetics, Safety, and Efficacy of SPRIX in 12 to 17 Year Old Patients vs. Adult Patients Undergoing Open Surgical ProceduresCompletedNCT01819610Phase 3
• Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid TumorsTerminatedNCT01804530Phase 1
• Effect of Tivantinib on the QTC Interval in Cancer SubjectsCompletedNCT01699061Phase 1
• A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT01588678Phase 1
• Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer SubjectsCompletedNCT01517399Phase 1

← Daiichi Sankyo overview and focus areas